On August 29, 2023, in connection with the termination of the Master Services Agreement, Sandra A. Gardiner notified Anebulo Pharmaceuticals, Inc. of her resignation as the Company?s Acting Chief Financial Officer, including as the Company?s principal financial officer and principal accounting officer, effective as of the Termination Date. Ms. Gardiner has offered to provide transition support services to her successor following the Termination Date on a limited basis to the extent needed, subject to further discussion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | +0.33% | +2.03% | +24.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.38% | 78.06M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ANEB Stock
- News Anebulo Pharmaceuticals, Inc.
- Anebulo Pharmaceuticals, Inc. Announces Resignation of Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer